Aggressive management of hypertension and dyslipidemia, along with lifestyle changes, are crucial for preventing cardiovascular disease in patients with diabetes, whereas the macrovascular benefits of intensive glycemic control remain uncertain.
Answers are grounded in this paper and cite their sources.
Reinforces hypertension and dyslipidemia control as priorities in diabetes; leaves open macrovascular benefits of intensive glycemic control.
Type 2 diabetes is a worldwide epidemic. Cardiovascular diseases remain the major cause of death in patients with diabetes, partly because of the association of diabetes and the metabolic syndrome. In this review, we will discuss the evidence for treatment and prevention of cardiovascular diseases in patients with diabetes. Aggressive treatment of hypertension and dyslipidemia is at the cornerstone in the management of heart disease in those patients. Despite its known benefit on the prevention of the microvascular complications of diabetes, intensive glycemic control may or may not have a significant effect on reducing macrovascular diseases. Finally, lifestyle changes and other cardiovascular therapies aimed at preventing heart disease may also prevent or delay the development of diabetes.
No takes yet. Share an insight, caveat, or question.
Lteif et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: